Article -> Article Details
Title | Nitric Oxide Test Market Strategic Analysis, Revenue by 2023 |
---|---|
Category | Fitness Health --> Medicine |
Meta Keywords | Nitric Oxide Test Market |
Owner | vinit |
Description | |
Market Highlights Increasing prevalence of respiratory diseases, availability
of wide range of products for the diagnosis, and treatment of asthma, chronic
obstructive pulmonary disease, as well as other lung disorders drive the
market. Additionally, increasing research and development activities,
technological advancements to identify the causes and risk factors for
respiratory diseases, and developing new solutions to minimize patient exposure
are other major drivers fuelling the global market growth. However, lack of
awareness about nitric oxide test likely to restrains the market growth. The global nitric
oxide test market is expected to grow at a CAGR of 5.4% during
the forecast period. An exhaled nitric oxide test is primarily used for the
diagnosis and treatment of asthma. Other indications for nitric oxide testing
are chronic obstructive pulmonary disease, cystic fibrosis, and pulmonary
arterial hypertension. Nitric oxide test measures the level of nitric oxide gas in
the sample of exhaled breath, and the results are indicated by the change in
the color of the test strip. Nitric oxide test strips and nitric oxide monitors
are the most widely used devices to diagnose various respiratory diseases. The
test is found to be quite familiar to the population living in developed
countries than in the developing and underdeveloped regions across the world. Major Players in the Market: Some of the key players in the global market are BERKELEY
TEST LIMITED (U.K), Human Power of N, Co. (U.K), ATP Nutritionals LLC (U.S.),
Neogenis (U.S.), CVS Health (U.S.), and Uniscience (U.S.). Regional Analysis The Americas account for the largest share of the global
nitric oxide test strip market owing to the rising demand for medical devices
and instruments in healthcare institutes and diagnostics laboratories.
Increasing efforts from asthma management by healthcare providers and
government through surveillance at national and state levels are also boosting
the growth of the market. As per the Centers for Disease Control and Prevention
(CDC) in 2015, 24,633 people were diagnosed with asthma and the number has increased
over past few years. Europe is the second largest market owing to an increasing
focus on lung disorder, increasing adoption of home care, and extensive
research on asthma, chronic obstructive pulmonary disease, and their prevalence
in European countries. In Asia Pacific, the prevalence of nitric oxide test is
increasing at the fastest pace as a result of increasing prevalence of asthma,
rising geriatric population, increasing focus on health care, and availability
of treatment options for various respiratory diseases. According to the data
from GLOBOCAN, in 2012, the age-standardized rate (ASR) of incidence of
gastrointestinal diseases in Asia Pacific was 15.8 and mortality was 11.7 per
100,000. According to World Health Organization (WHO), the geriatric population
in China in the year 2013 was 22.6 million, which is expected to reach 90.4
million by 2050. In Asia Pacific, environment population is a major risk factor
for asthma and lung diseases, which mainly affects the elderly population, and
children. In the Middle East and Africa, the prevalence of respiratory
diseases is increasing, accelerating the growth of the market at a steady pace.
Furthermore, growing demand |